Cello has made its first acquisition of the year by adding Mash Health to its roster of companies.
AIM-listed marketing group Cello will spend up to £1.5 million on buying the UK and US operations of Mash Health.
Under the terms of the deal, an initial £600,000 is due on completion of the transaction with an additional performance related consideration of up to £900,000.
Mash Health provides consultancy and communications services to pharmaceutical, nutraceutical and consumer healthcare clients such as GSK and Danone.
The business was founded in 2009 and has its bases in London and New Jersey. It will join Cello’s healthcare division Cello Health.
More on acquisitions by Cello:
Cello Health chairman Stephen Highley says that Mash Health is a ‘well-established’ brand particularly in the consumer end of the pharmaceutical space.
He adds, ‘This acquisition further reinforces our strong position in the consumer healthcare market.
‘We have already worked closely with Mash on a range of client assignments and are looking forward to continuing to build on our exciting progress.’